Back to News
Market Impact: 0.4
Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Spyre Therapeutics reported positive 12-week induction data from Part A of its Phase 2 SKYLINE trial for SPY003 in patients with moderately-to-severely active ulcerative colitis. The favorable clinical readout supports development of the investigational extended half-life anti-IL-23 antibody and is likely to be a positive catalyst for SYRE shares, although specific efficacy and safety metrics were not disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.50
Ticker Sentiment
SYRE0.78
More News
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- ‘There’s nothing temporary about a temporary store’: How Spirit Halloween’s CEO took it from 130 stores to 1,550—and swallowed your mall’s Hot Topic